Skip to main content

An analysis of biotechnology and non-biotechnology R&D capabilities in the Indian pharmaceutical industry

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

The commercialization of biotechnology requires very serious and intense research capabilities. The pharmaceutical industry has been one of the early exploiters of biotechnology because of the existence of such capabilities. This feature has been observed worldover and the literature is replete with information on how firms have evolved various strategies to meet this requirement. The present paper is an attempt to assess the R&D capabilities in the pharmaceutical companies in India in the context of biotechnology commercialization. A study was made of the R&D capabilities of 33 companies. These companies represent 3 categories of the Indian industry: purely medicinal chemistry based pharmaceuticals; diversified (both medicinal chemistry and biotechnology); dedicated biotechnology companies. Discriminant analysis was performed (i) to understand the distinctiveness of the three groups of companies and (ii) to understand the characteristics of their R&D capabilities. With respect to eight of the ten chosen parameters like R&D intensity, skill intensity, linkages, output of R&D, size, age, R&D manpower as a proportion of total manpower and number of skilled R&D employees, the three groups are observed to be distinct from each other.

Document Type: Research Article

DOI: https://doi.org/10.1111/1467-9310.00052

Affiliations: National Institute of Science Technology and Development Studies, Dr. K. S. Krishnan Marg, New Delhi-110012, India

Publication date: 1997-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more